Ian Karp | executive |
John Leonard | executive |
David Lebwohl | executive |
Laura Sepp-Lorenzino | executive |
Glenn Goddard | executive |
Konstantinos Biliouris | analyst |
Joon Lee | analyst |
Mani Foroohar | analyst |
Ry Forseth | analyst |
Dae Gon Ha | analyst |
Maurice Raycroft | analyst |
Gena Wang | analyst |
Salveen Richter | analyst |
Luca Issi | analyst |
Yanan Zhu | analyst |
Greg Harrison | analyst |
Joseph Thome | analyst |
Liisa Bayko | analyst |
Rick Bienkowski | analyst |
Terence Flynn | analyst |
Eliana Clark | executive |
Brian Cheng | analyst |
Myles Minter | analyst |
Jay Olson | analyst |
William Pickering | analyst |
Silvan Tuerkcan | analyst |
David Lebowitz | analyst |
Steven Seedhouse | analyst |
Whitney Ijem | analyst |
Good morning and welcome to the Intellia Therapeutics' Third Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call.
As a reminder, all participants are currently in a listen-only mode.